Telix Pharmaceuticals announced successful alignment with the FDA on the Part 2 protocol design of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration resistant prostate cancer. The FDA confirmed that Part 1 safety data is sufficient to progress Part 2 into the U.S., where the therapeutic candidate will be tested in combination with three standard-of-care therapies. The company plans to submit an IND amendment to initiate Part 2 enrollment in the U.S.

Telix Pharmaceuticals announced an educational webinar scheduled for June 29-30, 2026, featuring clinical updates on neuro-oncology and theranostics approaches to address unmet needs in glioma and glioblastoma treatment. The webinar will include presentations from Telix's Chief Medical Officer and fireside chats with leading nuclear medicine and neuro-oncology physicians from European institutions.

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

Telix Pharmaceuticals announced positive Phase 3 Part 1 data for TLX591-Tx, a lutetium radio antibody-drug conjugate for metastatic castration-resistant prostate cancer. The study of 36 patients showed acceptable safety and tolerability when combined with standard-of-care therapies, with no new safety signals. Radiation exposure remained below established safety limits, and the company has initiated Part 2 randomized expansion in multiple jurisdictions.

Telix Pharmaceuticals announced completion of patient enrolment in the IPAX-2 Phase 1 study of TLX101-Tx (¹³¹I-iodofalan) for newly diagnosed glioblastoma. The study reached its maximum dose of 10GBq with no dose-limiting toxicities observed. The company is also advancing the pivotal IPAX BrIGHT Phase 3 trial for recurrent glioblastoma, marking the first radiopharmaceutical therapy to enter Phase 3 development for this indication.

Regeneron Pharmaceuticals' stock dropped 10.20% in premarket trading after its Phase 3 melanoma trial failed to meet its primary endpoint. While the high-dose fianlimab combination showed numerically higher progression-free survival (11.5 months vs 6.4 months), it missed statistical significance with a p-value of 0.0627. The company also announced a partnership with Telix Pharmaceuticals to develop radiopharmaceutical therapies.

Telix Pharmaceuticals announced publication of Phase 3 ZIRCON trial data showing that TLX250-Px PET/CT imaging may be effective in diagnosing not only clear cell renal cell carcinoma (ccRCC) but also non-clear cell renal cell carcinoma (nccRCC), with a 98% positive predictive value for malignancy. The exploratory analysis suggests broader clinical applications beyond the original ccRCC focus, potentially aiding in risk stratification and treatment decisions for renal cancer patients.

Telix Pharmaceuticals announced that its marketing authorization application (MAA) for TLX101-Px, a PET imaging candidate for glioma (brain cancer), has been validated and accepted for review in Europe. The application has entered a 210-day active assessment phase, with national marketing authorizations expected to follow a positive outcome. The product addresses a critical unmet need in Europe where no commercial FET-PET imaging product currently exists for glioma diagnosis and treatment monitoring.

Telix Pharmaceuticals announced dosimetry results from the Phase 2 OPTIMAL-PSMA trial of TLX597-Tx, a PSMA-targeting radioligand therapy for metastatic castration-resistant prostate cancer. The trial demonstrated low salivary gland and kidney uptake, supporting dose intensification and improved tolerability. Telix is initiating OPTIMAL-E, a Phase 2 study in earlier-stage metastatic hormone-sensitive prostate cancer, as part of its portfolio approach alongside TLX591-Tx.

Telix Pharmaceuticals announced an educational webinar scheduled for April 30, 2026 (AEST) featuring Dr. David N. Cade and Professor Louise Emmett discussing the evolution of PSMA-targeted radionuclide therapy and Telix's multi-product approach to prostate cancer treatment. The webinar will showcase data from the OPTIMAL-PSMA2 trial of TLX597-Tx (177Lu-DOTA-PSMA), Telix's novel second-generation small molecule candidate for lutetium therapy.

Telix Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to develop next-generation radiopharmaceutical therapies for solid tumors. Telix will receive $40 million upfront plus up to $2.1 billion in milestone payments and royalties. The partnership combines Telix's radiopharmaceutical platform with Regeneron's biologics expertise. Telix also reported Q1 revenue of $230 million (up 11% sequentially) and reaffirmed its 2026 guidance of $950-970 million. Additionally, the FDA accepted Telix's resubmitted application for Pixclara for brain cancer imaging.